
Tianjin TEDA Biomedical Engineering Company Limited
8189.HKHKSEBasic MaterialsAgricultural Inputs
Latest quote
HK$0.26
−HK$0.01 · -3.70%
8189.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteTianjin TEDA Biomedical Engineering Company Limited, founded in 2000 and based in Tianjin, People's Republic of China, is a diversified enterprise primarily involved in the research, development, manufacturing, and distribution of biological compound fertilizer products throughout the PRC. Its operations are organized into two main divisions: Biological Compound Fertilizers and Elderly and Health Care Services. The company's agricultural offerings encompass active fertilizers and various tailored blends of nitrogen, phosphorus, and potassium, specifically formulated to promote balanced growth for a range of crops including grains, fruits, and vegetables. Beyond agriculture, Tianjin TEDA Biomedical provides integrated care for the elderly and comprehensive health services. This includes leasing essential equipment for seniors and offering specialized consulting, advisory, and assessment solutions. Furthermore, the company develops and licenses electroencephalography (EEG) diagnosis detection services, utilizing its expertise in EEG technology for diagnostic applications. Its extensive activities also cover the research, development, production, and practical application of biomedical science and technology projects, alongside regional soil resource conditioning and remediation, and the provision of soil environmental quality standards research services.
- Industry
- Agricultural Inputs
- Sector
- Basic Materials
- Headquarters
- CN
- CEO
- Li Sun
- Listed since
- Jun 18, 2002
- Employees
- 273
Market position
Day range
Current HK$0.26
52-week range
Current HK$0.26
- Open
- HK$0.255
- Previous close
- HK$0.27
- Volume
- 365K
- 0.53× average
- Average volume
- 685.4K
- Average daily volume
- Market cap
- 554.81M HKD
- Beta
- -0.44
- Market reference 1
- 50-day average
- HK$0.1618
- +60.65% above average
- 200-day average
- HK$0.2597
- +0.11% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 650.28M CNY
- P/E (TTM)
- -3.55×
- P/B (TTM)
- 38.01×
- P/S (TTM)
- 0.71×
- EV / EBITDA
- -45.41×
- Earnings yield
- -15.53%
- Free cash flow yield
- -11.03%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 5.22%
- Operating margin
- -7.18%
- Net margin
- -19.75%
- Return on equity
- -723.42%
- Return on assets
- -33.39%
- Return on invested capital
- -20.64%
Financial health
- Debt / equity
- 8.98×
- Current ratio
- 0.75×
- Altman Z-score
- 0.02
- Piotroski F-score
- 4 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 509.43M CNY | 385.48M CNY | 398M CNY | 403.73M CNY | 476.38M CNY |
| Cost of goods sold | 474.68M CNY | 368.51M CNY | 376.63M CNY | 433.28M CNY | 430.78M CNY |
| Gross profit | 34.75M CNY | 16.97M CNY | 21.37M CNY | 14.82M CNY | 45.6M CNY |
| Research and development | 4.03M CNY | 1.1M CNY | 1.32M CNY | 1.14M CNY | 3.5M CNY |
| Selling, general, and administrative | 32.22M CNY | 34.26M CNY | 29.91M CNY | 37.49M CNY | 48.76M CNY |
| Operating expenses | 58.32M CNY | 45.35M CNY | 31.2M CNY | 38.51M CNY | 63.99M CNY |
| Interest income | 75.59K CNY | 47.97K CNY | 249.97K CNY | 762.8K CNY | 430.83K CNY |
| Interest expense | 3.69M CNY | 4.58M CNY | 5.17M CNY | 6.4M CNY | 5.47M CNY |
| Depreciation and amortization | 9.25M CNY | 8.2M CNY | 11.63M CNY | 15.39M CNY | 9.51M CNY |
| Operating income | −23.57M CNY | −28.38M CNY | −9.83M CNY | −24.41M CNY | −18.39M CNY |
| Net income | −88.47M CNY | −27.8M CNY | −20.16M CNY | −27.45M CNY | −42.26M CNY |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -0
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
8189.HK peers
Continue in GoAI
Research 8189.HKresearch.disclaimer





